Cargando…

Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?

BACKGROUND: Sepsis may be accompanied by acute respiratory distress syndrome (ARDS) in patients admitted to intensive care units (ICUs). It is essential to identify prognostic biomarkers in patients with sepsis and ARDS. OBJECTIVE: Determine whether changes in the level of serum fibroblast growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xing, Shen, Hua, Zhou, Tinghong, Cao, Xiaoyu, Chen, Ying, Liang, Yan, Lu, Ting, He, Jiafen, Dou, Zhoulin, Liu, Chuankai, Tang, Yong, Zhu, Zexiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216835/
https://www.ncbi.nlm.nih.gov/pubmed/34154595
http://dx.doi.org/10.1186/s12931-021-01778-w
_version_ 1783710499674783744
author Li, Xing
Shen, Hua
Zhou, Tinghong
Cao, Xiaoyu
Chen, Ying
Liang, Yan
Lu, Ting
He, Jiafen
Dou, Zhoulin
Liu, Chuankai
Tang, Yong
Zhu, Zexiang
author_facet Li, Xing
Shen, Hua
Zhou, Tinghong
Cao, Xiaoyu
Chen, Ying
Liang, Yan
Lu, Ting
He, Jiafen
Dou, Zhoulin
Liu, Chuankai
Tang, Yong
Zhu, Zexiang
author_sort Li, Xing
collection PubMed
description BACKGROUND: Sepsis may be accompanied by acute respiratory distress syndrome (ARDS) in patients admitted to intensive care units (ICUs). It is essential to identify prognostic biomarkers in patients with sepsis and ARDS. OBJECTIVE: Determine whether changes in the level of serum fibroblast growth factor 21 (FGF21) can predict the 28-day mortality of ICU patients with sepsis and ARDS. METHODS: Consecutive sepsis patients were divided into two groups (Sepsis + ARDS and Sepsis-only), and the Sepsis + ARDS group was further classified as survivors or non-survivors. Demographic data and comorbidities were recorded. The Sequential Organ Failure Assessment (SOFA) score and serum levels of cytokines and other biomarkers were recorded 3 times after admission. Multiple Cox proportional hazards regression was used to identify risk factors associated with 28-day mortality in the Sepsis + ARDS group. Multivariate receiver operating characteristic curve analysis was used to assess the different predictive value of FGF21 and SOFA. RESULTS: The Sepsis + ARDS group had a greater baseline SOFA score and serum levels of cytokines and other biomarkers than the Sepsis-only group; the serum level of FGF21 was almost twofold greater in the Sepsis + ARDS group (P < 0.05). Non-survivors in the Sepsis + ARDS group had an almost fourfold greater level of FGF21 than survivors in this group (P < 0.05). The serum level of FGF21 persistently increased from the baseline to the peak of shock and death in the non-survivors, but persistently decreased in survivors (P < 0.05). Changes in the serum FGF21 level between different time points were independent risk factors for mortality. No statistical difference was observed between the AUC of FGF21 and SOFA at baseline.  CONCLUSION: A large increase of serum FGF21 level from baseline is associated with 28-day mortality in ICU patients with sepsis and ARDS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01778-w.
format Online
Article
Text
id pubmed-8216835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82168352021-06-23 Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS? Li, Xing Shen, Hua Zhou, Tinghong Cao, Xiaoyu Chen, Ying Liang, Yan Lu, Ting He, Jiafen Dou, Zhoulin Liu, Chuankai Tang, Yong Zhu, Zexiang Respir Res Research BACKGROUND: Sepsis may be accompanied by acute respiratory distress syndrome (ARDS) in patients admitted to intensive care units (ICUs). It is essential to identify prognostic biomarkers in patients with sepsis and ARDS. OBJECTIVE: Determine whether changes in the level of serum fibroblast growth factor 21 (FGF21) can predict the 28-day mortality of ICU patients with sepsis and ARDS. METHODS: Consecutive sepsis patients were divided into two groups (Sepsis + ARDS and Sepsis-only), and the Sepsis + ARDS group was further classified as survivors or non-survivors. Demographic data and comorbidities were recorded. The Sequential Organ Failure Assessment (SOFA) score and serum levels of cytokines and other biomarkers were recorded 3 times after admission. Multiple Cox proportional hazards regression was used to identify risk factors associated with 28-day mortality in the Sepsis + ARDS group. Multivariate receiver operating characteristic curve analysis was used to assess the different predictive value of FGF21 and SOFA. RESULTS: The Sepsis + ARDS group had a greater baseline SOFA score and serum levels of cytokines and other biomarkers than the Sepsis-only group; the serum level of FGF21 was almost twofold greater in the Sepsis + ARDS group (P < 0.05). Non-survivors in the Sepsis + ARDS group had an almost fourfold greater level of FGF21 than survivors in this group (P < 0.05). The serum level of FGF21 persistently increased from the baseline to the peak of shock and death in the non-survivors, but persistently decreased in survivors (P < 0.05). Changes in the serum FGF21 level between different time points were independent risk factors for mortality. No statistical difference was observed between the AUC of FGF21 and SOFA at baseline.  CONCLUSION: A large increase of serum FGF21 level from baseline is associated with 28-day mortality in ICU patients with sepsis and ARDS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01778-w. BioMed Central 2021-06-22 2021 /pmc/articles/PMC8216835/ /pubmed/34154595 http://dx.doi.org/10.1186/s12931-021-01778-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Xing
Shen, Hua
Zhou, Tinghong
Cao, Xiaoyu
Chen, Ying
Liang, Yan
Lu, Ting
He, Jiafen
Dou, Zhoulin
Liu, Chuankai
Tang, Yong
Zhu, Zexiang
Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?
title Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?
title_full Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?
title_fullStr Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?
title_full_unstemmed Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?
title_short Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS?
title_sort does an increase in serum fgf21 level predict 28-day mortality of critical patients with sepsis and ards?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216835/
https://www.ncbi.nlm.nih.gov/pubmed/34154595
http://dx.doi.org/10.1186/s12931-021-01778-w
work_keys_str_mv AT lixing doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT shenhua doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT zhoutinghong doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT caoxiaoyu doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT chenying doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT liangyan doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT luting doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT hejiafen doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT douzhoulin doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT liuchuankai doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT tangyong doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards
AT zhuzexiang doesanincreaseinserumfgf21levelpredict28daymortalityofcriticalpatientswithsepsisandards